<DOC>
	<DOCNO>NCT02648048</DOCNO>
	<brief_summary>This single arm , multicenter , open-label , Phase 1b study evaluate safety tolerability vismodegib combination pirfenidone participant idiopathic pulmonary fibrosis ( IPF ) currently treat pirfenidone .</brief_summary>
	<brief_title>A Safety Tolerability Study Oral Vismodegib Combination With Pirfenidone Participants With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Have diagnosis IPF 5 year time screening , confirm baseline Tolerated dose pirfenidone 16022403 mg daily ( QD ) minimum 24 week require prior screen Greater equal ( &gt; = ) 50 percent ( % ) &lt; =100 % predict forced vital capacity ( FVC ) screen Stable baseline lung function evidence difference le ( &lt; ) 10 % absolute FVC measurement ( liter ) screen Day 1/Visit 2 prior enrollment &gt; =30 % &lt; =90 % predict diffusion capacity lung carbon monoxide screen Agree use protocol define method contraception Male participant must agree donate semen study least 2 month ( per local requirement ) last dose vismodegib Agree donate blood blood product study least 9 month ( per local requirement ) last dose study treatment Prior treatment vismodegib Hhpathway inhibitor Evidence know cause interstitial lung disease Hospitalization due exacerbation IPF within 4 week prior screen Lung transplant expect within 6 month screen Evidence clinically significant lung disease IPF Postbronchodilator force expiratory volume 1 second/FVC ratio &lt; 0.7 screen Any clinically significant medical disease ( IPF ) associate expected survival &lt; 6 month , likely require change therapy study Class IV New York Heart Association chronic heart failure historical evidence leave ventricular ejection fraction &lt; 35 % Known current malignancy current evaluation potential malignancy Known immunodeficiency , include , limited , human immunodeficiency virus infection Evidence acute chronic hepatitis know liver cirrhosis Creatinine clearance &lt; 30 milliliter per minute , calculate use CockcroftGault formula</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Vismodegib</keyword>
	<keyword>Pirfenidone</keyword>
</DOC>